Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

AIFORIA TECHNOLOGIES OYJ, Q2'24

By Inderes8/29/2024, 7:00 AM
Aiforia Technologies

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:11 - 11:14

Good morning and welcome to Aiforia Technologies Plc's first half earnings announcement. Today, we will share some brief results, a financial review, and discuss our strategy for moving forward. So it was a really interesting and busy six months from January to June 2024. And we actually got progress in multiple areas, you know, in this market that we are in. So, in digital pathology AI. So it's really kind of picking up. The market is so large that there's a huge demand. So there's a customer with the active problem recognition. And they are actively searching for solutions. So, I've been talking about how the market is moving forward because the demand is there. So the aging population's need for technology to improve efficiency and bring other benefits to this market is happening big time at the moment. So there was this phase where we dealt with the early adopters, and I think we are now moving past the first kind of phase. Okay, so we are crossing the cusp. So we are with the first major customers on the clinical side as well. And, what happened, um, some of the things here. So, the Mayo Clinic, one of our first and probably our most important reference customers, is what we have. So we won Mayo about two years ago already. So we've been delivering different solutions. On the clinical side, the research side, and in cooperation, our partnership with the Mayo Clinic is progressing well. So, a big thing in January that we did. So we started to commercialize the colorectal cancer model built together by Mayo Clinic, with commercialization happening through Aiforia. And this is something new. So it's about having an eye for AI tools and then combining them with predictive models. And then they can predict the type of patient outcomes using those models. Then in a European area. I think this was a really nice start because we secured our first major customers last year. We want the Veneto Region, which is more or less the same size as the country of Finland. What comprises a population. So 5.5 million people at 12 different hospitals. We sold all our kinds of COVID mask solutions. So those have been implemented and delivered, and now they are waiting for the new scanners to arrive so that they can ramp up the volume. But that was a starting point. There are multiple opportunities in Italy at the moment. So, we want a big deal in Spain. So, we've made good progress in France. So multiple opportunities in the pipeline. So some nice wins. And I think one of the big ones was the Paris hospital region. So they've been announcing already that they started using the AI from Aiforia against our main competitors, and chose us to secure the budget. So, it is in a purchasing process. So, that's probably the biggest hospital group in Europe. So, it's a really significant thing for us. But all in all, Europe has made a lot of good progress. And of course, the female deal, I will cover that a bit later. So, I think we are very happy with what's happening in the European area. And of course, on the product side. We also focus on the pre-clinical sector, bringing new, attractive offerings to customers. We conducted the funding round. Roughly about 10 million raised. So that's really a positive thing for us going forward. Before delving into the numbers, I think it's important to recognize the significance of the deals we've secured, given that we have multiple competitors. We're talking about a handful that offer similar solutions and certifications. But I believe that, okay, we have the strongest position on actual live implementation and significant customer wins. I mentioned the Mayo Clinic. The breast cancer solutions have been live on the clinical side for over a year now. So, there are over 70 pathologists working on our creative development platform. So, they're building their own AI models. And there's a lot of scientific papers coming out from that activity. AI models, that's okay. So, in later stages, to take it and put it into production at a clinical site. But Mayo Clinic is going strong in the European region. Fimlab Laboratories, a group from a temporary region in Finland. So, that's a big thing. I noticed that some of our competitors also announced the umbrella contract, which was a public tender that we responded to. And, so there are at least three different vendors under the umbrella contract, which is nice because it gives the customer a choice if they need that. But what I can say about AI for Aiforia's role here is that they selected vendors for nine different areas, and Aiforia was chosen for all of those. Some other vendors were considered for some areas, but not all. So we were the only ones chosen in all nine categories, category number ten. Nobody was chosen on that one. So, it relates to skin cancer. But all of those solutions or categories that they chose have somebody. So we were chosen, and what is even more important, after the first half of the year, we also received our first order. We are currently in a phase of our journey delivering solutions to Fimlab Laboratories. So we won now in the categories one, two, and three where there was a competition. But, we received the purchase order in this case, and it's a sizable deal. The entire tender is approximately 6 million. And it's a public information. However, the eye part is not valued at 6 billion. So it's a little bit less, but still a really significant deal from our perspective. So, now the thing is that we need to deliver it really carefully and well, and we have a good chance of going forward with the rest of the areas as well. And so that's positive news. And it's really a frontrunner in AI adaptation in Finland. So it's a big, big thing for us then. Castile and León Region Health Management in Spain. So, that was a significant point as well. So we do it together with Sectra, the Swedish image management vendor. So together, it's a multi-year contract and a sizable deal. And we sold our AI-powered pathology image analysis solutions for prostate and lung cancer there. So, it's now moving to the implementation phase. Uh, I mentioned about the Veneto. It's a big one, with 5.5 million people. It's a great reference in the Italian market because now there are ten similar types of regions in Italy. So, they all have funding from the European Union. So they have this Covid recovery fund in place, and they need to invest that money before the end of 2026. So I think there's a good chance of really capturing the opportunity in the Italian market. But having Veneto as one of the leading regions there is an example and a reference. So that helps us in pursuing the other ones. Catania obviously. We already received an order from there, and PathLake in the UK. So it's in the delivery phase, and that's going nicely as well. But from a business perspective, the biggest change occurred in Europe in the first half of the year. And we are really confident about this region moving forward nicely. Then briefly about the numbers, our CFO will go deeper into the numbers, but this just highlights our revenues grew by 43%. Which is substantial. The business remains largely international. With 10% coming from Finland and 90% from other regions. The European area was picking up nicely. Keep in mind that we are still dealing with relatively small numbers. If we secure a big deal in Europe, these percentages will change very quickly. But all in all, the positive sign is that there's decent growth on that side. And also the order book was growing nicely. There's about €800,000 growth on that side. I would also like to point out that most of the big deals we closed in the first half, we haven't recognized the revenue from them. So we closed the deals, may have already received the purchase orders, and so on. But when we deliver, we start recognizing the revenue and also note that these are multiyear contracts. Meaning that, okay. So you can see some of those items in the backlog already but not necessarily on the revenue side. The backlog was growing nicely. As well as the revenue, we continue investing because it's a new business, and we need to be very careful to deliver what we need on the AI side, ensuring that we have all the APIs and supporting software elements in place so that we can integrate with surrounding systems and so on. Our costs, I think we are moving in the right direction. They are under control and slightly less than a year ago, and we still need to maintain a strong focus on that side, so that we have a healthy amount of cash in our bank account, and we want to keep it that way to ensure we can continue the company successfully and really capture the opportunity in this market. And yes, the cash balance is the last one. About 17.9 million. But now I will hand over to William to continue with the numbers. And I will come back a bit later and talk about the strategy and going forward. Thank you. And good morning to everyone.

William
11:15 - 14:38

I think you revealed all the numbers already, but let's repeat those one more time. Now, here we go. Next, I will go through the first half numbers. The revenue growth was, as I said, 43%, or from 400,000 to 1.4 million. The growth came mainly from the clinical side. And that protein contributed to about 40% of our revenue base; EBITDA was -4.2 million and the EBIT was -€6 million. The equity ratio was 67%. And we did have about 18 million cash at the end of the period. Order book growth was 34%, as you said, from 800,000 to 3.2 million. We did have about 76 employees working for Aiforia on average during the first half. That's an increase of 7%, compared to 10% a year earlier. And we invested, I said 2.7 million, mainly in research or intangible assets, R&D. Only a fraction of that is in tangible assets. We don't need any raw materials, warehousing, or anything like that. So, it's pretty much business as usual. Uh, investments declined by about half a million from the figures of the previous year. And that is because our fixed costs went down about 7%, from 8.4 million to 7.8 million. And, as employee costs went up about 5%, the other operating costs went down 16%. And that is because we were capable of, first, hiring new software developers. But at the same time, we were capable of decreasing the number of software consultants working for us. And also we were able to trim some of the costs from the cloud spending. We are currently running our fixed costs at slightly over the 15 million level. And, I keep a pretty close eye on those costs. The cash flow from operations improved by 800,000 from the previous year, from -4.6 million to -3.8 million. And I said we have promised that figure to be breakeven. By the end of next year. Back to you.

Unknown 1
14:40 - 27:23

Okay. Thank you very much. Thanks. So we are in an interesting market. So, that's what we do. So we actually automate what pathologists are doing. So we are, uh, supporting the diagnostic. So we perform quantitative analysis on those tissue samples processed in that process, enabling analysis to determine whether there is cancer present or not. And how serious is that, and what type of treatment is needed? So the market is interesting. We are dealing with very small sample sizes that contain a huge amount of data. So we are dealing with the size of the files. And, uh, it's really important that. So, you captured the information from those slides really precisely, carefully, and efficiently. So, that's what we do. So, as I said, there is a market. So there is an active problem recognition because there are about 100,000 pathologists in the world. There are about 3 billion glass slides diagnosed every year, typically using the traditional process with a microscope, now transitioning to digital and leveraging AI to automate the process. So the demand is there because the number of pathologies is not going up. Cancer cases are increasing, and the need for diagnosis is really on the rise. And there's a growing gap between those two things. And now we have proven that. We have the technology, we have good references, and we can help sort out those issues. And that's the business where we are at. So, we are really focusing on capturing the clinical opportunity, ensuring that they can handle the large workflows they have, and we can also open up new opportunities to leverage the digital information. As an example, the product that we developed together with Mayo Clinic, the CRC, enables you to take it to the next level. So you leverage the AI and quantitative analysis. Predictive models enhance patient outcome prediction and improve treatment decisions, showcasing the opportunities AI opens up. And of course in research in pharma. So we are still strong. And we want to make sure that we keep those good customers and sell models to those customers because they also have a need when it comes to new truck developments. So, extensive studies need to be conducted beforehand. So we have tools for that. We have the tools to build AI models and streamline drug development, allowing us to bring products to market faster. So we have a good offering in place. But obviously, moving forward into the coming years, we need to grow. And we've put a lot of effort into that. We have captured some nice opportunities now. So we need to make sure that we deliver on those exceedingly well. We will upsell those customers because we have sold them five AI models, but they will probably need 20 or 30 more going forward. So, considering all of these bigger customers that we have, we need to ensure they stay and they grow. And then, we need to acquire additional, similar types of customers over the next 2 or 3 years. Then the market will start scaling in volume. There's regulation in place. There are references in place. There's a kind of blueprint for other hospitals on how to implement these solutions. They can be confident, given that leading organizations like Mayo Clinic, Paris Hospital Region, Veneto Region Health Authority, Fimlab Laboratories, or any of these players, are using it. Then other kinds of organizations can be confident as well, leveraging the benefits and starting to use the solution. The prerequisites are there. The need is present, and so are the solutions. And we just need to make sure that we can scale and maintain confidence by ensuring our products are best in class and reliable. Because, of course, we are dealing with very critical matters. So we cannot afford mistakes, as you know. When we implemented the cardiovascular disease (CVD) solution, for example, it was tested against human pathologists, ensuring that the AI performed at least at the same level as humans. Subsequently, it received the necessary approvals, thus improving the efficiency of pathologists in this field. But really, there's a lot of focus on growth in the coming years, ensuring that our product offerings remain competitive. At the moment, we have significant advantages over key competitors. Currently, most of the competition relies on so-called heatmaps to indicate whether a sample is cancerous or not, requiring pathologists to focus traditionally. As you know, we delve a little deeper. We conduct quantitative analyses. We build the tools at a pixel level, allowing us to capture even the smallest piece of information from the slides. Then we conduct quantitative analyses again. We perform calculations on different cells and so forth. So we provide all the necessary information for diagnoses in a pre-prepared report. And that's also an extremely important aspect. First, you see the slide, then you receive the report with all the calculations. The pathologist then verifies the results. Further, it leads to a treatment decision by the physician responsible for making such decisions. It is truly an automation tool, but also serves as a gateway to capabilities beyond human reach. We indeed have a fantastic team in place, forming a strong technical team. Moreover, we have a very strong science team and an equally capable sales team. Ensuring our small team comprises top talent and performs well is crucial, and currently, we are very pleased with our staff. They have been delivering the best solutions globally. We have also been successful in introducing these solutions to the market. In this way, these are our focus areas moving forward. Considering our business targets for the mid to long term. We aim to be involved on the clinical side, ensuring we provide automation. This means delivering AI tools – not just the algorithms, but also all the necessary APIs and tools required for integration into hospital systems, enabling collaboration with other required systems, positioning us as a reliable software company that delivers, maintains, and develops its products. That's the business we are engaged in. By 2027, we should achieve our first profitable year, as currently, it's a phase of investment. This is a venture into new business territory, establishing a solution, and opening up the market. We have been doing this successfully. By 2027, we anticipate being on a remarkable number. This presents a massive opportunity. Achieving over one hundred million in sales should be our target for this decade. Furthermore, we can leverage this technology in several other fields because ultimately, when we consider AI for our technology company, we possess an incredible platform capable of diagnosing vast image files, targeting incredibly minute details. We could explore various solutions in this realm. For instance, consider Force Medica from the US market. This was one of the significant deals in the first half of the year. Specifically, in the field of veterinary pathology, they are developing their own device and a comprehensive end-to-end solution for that market. And we are providing the technology for them so that, when they start mass production of their devices, they are equipped. Aiforia Technologies' initial purchase was primarily to acquire the development platform. But going forward, it's an opportunity to grow that alongside their sales as well. Of course, we need to secure those big accounts and ensure they are satisfied and using our services. That is what we are aiming to achieve. Short term, this year. With only about four or five months left in this year, but still time to make progress. Looking towards next year. We will introduce these AI models to the market. As you all know. There was a regulation change two years ago from the CVD standpoint. We've been addressing these issues and will soon introduce new models to the market. I think the solutions are ready, but getting the necessary regulatory approvals is the next step. Then we can make the announcements. Progress is being made. And, of course, focusing on partnerships. I believe this is a critical aspect. We collaborate with major cloud providers like Google and Amazon, which is significant. Providing the platform and technology behind it. We also work with scanner manufacturers, image management companies, and picture archiving solution providers. We partner with all of these entities. In most cases, this collaboration stems from successful customer engagements. We implement these systems first, but notable sectors such as the Mayo Clinic are now in the Castile and León Region in Spain. This is advancing nicely. There are several similar companies with which we collaborate in this area, sometimes even with competitors, as they possess capabilities we might lack. And we certainly offer assets they don't have. Thus, we also collaborate with them. Then, achieving these key accounts, where the potential revenue is over $500,000 or more per year begins. It doesn't mean that in the first year it will be $500,000, But it has the opportunity to grow, as this is a "land and expand" type of strategy where we initially implement a couple of AI models and bring them into production. So, we can then start expanding the offering to those customers. But that's a really important one. And we've been moving forward nicely with that target. And then, aiming for cash flow positivity by the end of next year. So, we are on track to achieve that as well. But yeah, there's a lot we need to do. We need to close deals. We need to keep costs under control. And currently, it feels okay. So, we are on the right track in doing all of those and delivering on them. Now it's time for Q&A. I don't know if Matthew wants to join me at the front as well. So if it's a difficult question, Then I will refer to this gentleman here.

Matthew
27:24 - 27:45

It's interesting; I could first address our revenue for the first half. Obviously, it was lower than in the second half of last year, and the U.S. declined from the second half of last year to the first half of this year. And considering the launch of new models, which seemed to at least go live. And of course, they say they're doing significant work with Aiforia. Can you explain a bit about what's going on with the U.S. revenue?

Unknown 1
27:45 - 30:05

Well, it's, I think, okay, we're discussing small numbers, and as I mentioned in the beginning, if you close one deal, then it is higher, otherwise lower. So, Mayo Clinic continues to show slight growth. We could see a bit faster growth with them. But it will come. The important thing is that Mayo Clinic has used these in production. And they have plans to increase usage, so that's happening. And research work is ongoing. Mayo Clinic remains solid. But then in the U.S., there's this FDA compliance track that we are now advancing on the regulatory side. But the FDA hasn't really made up its mind on how to proceed. Currently, to have an FDA approved solution, you need an FDA-approved scanner, an FDA-approved image management system, and an FDA-approved AI, and all of these components need to work together. So none of the competition has those. We've been able to sell on the clinical side, having these processes in place, like the laboratory-developed test process. Larger organizations like Mayo Clinic develop and continue these processes themselves. But it's a costly process. To be fair, I think it's slowing down the adoption in the US. On the positive side, there are those CPT codes, the reimbursement codes for breast cancer, already in place. So that could be something that starts to pick up faster because it's in the US. It all comes back to the money issue. We've been closing pre-clinical deals. We closed a deal with Zomedica, which is in the veterinary area, because there is no regulatory burden on that side. So those are the kinds of quicker growth opportunities. Most of the competition is also now focusing on the pre-clinical side. But we have those few hospitals and we are growing them. And when the regulatory environment changes, then I think the US will ramp up fairly quickly. But I am not sure if this answers your question or not. So, yes.

Matthew
30:05 - 30:27

And the next question as well. Almost. But I'll continue on it. That's still the case, obviously, in Europe. It's been very good progress for you. And there the regulatory framework is in place and you have the COVID models. So is it right to assume that once the FDA framework is in place and you start getting those FDA-approved models, that should be an unlock for growth in the US?

Unknown 1
30:28 - 31:31

Um, yes. As a cautious answer. Yes and no. I said yes, obviously. Because it's a good thing when you have that approval. So then it gives confidence to the end customers to purchase a solution. But we have examples where one of the competitors has FDA-approved AI models. They haven't sold those because the models are only linked to one image management system and one scanner. So that's a Philips scanner. But if the customer wants a different scanner, then it's not an FDA-approved solution anymore. So in a way, that's the difficulty. But I think the US market is expecting to have solid products that don't need too much tailoring, just a little bit, so you can fine-tune it, but it has to be something that they can buy, implement, and start using immediately. But having said that, there are really significant opportunities in the U.S. market as well.

Matthew
31:33 - 31:49

Then, on the key accounts, you have the goal of securing 15 of those within the next one and a half years. You haven't yet commented on how many you have right now, but is it correct to assume that most of the ones you publish, at least in a press release, would be within that region?

Unknown 1
31:49 - 31:57

Yes. Yeah, yeah. But as I said, so we are on track to achieve that goal and overachieving as well. Yeah.

Matthew
31:58 - 32:01

And I guess Europe will be the biggest driver, at least in the short term.

Unknown 1
32:01 - 32:04

Europe is in a short-term period for sure. Yeah.

Matthew
32:04 - 32:29

That's helpful. You pass on the rail. You have the target of achieving positive profitability in 2027. And obviously, with the current growth rate, that's probably not going to cut it for 2027. So, you would need to have faster relative growth going forward. So are we looking at something closer to 27 in terms of a holistic scenario, or how do you view the revenue?

William
32:29 - 32:45

That must be the case. I assume that the growth has to pick up a little bit more. We must also be very cautious with the cost levels. So, those are the combination of two factors that bring us to profitability for 2017.

Unknown 1
32:45 - 32:46

Yeah.

Matthew
32:46 - 32:58

And the assumptions going into that goal and what it takes to achieve it, I guess there is, of course, winning new customers. But I guess the regulatory side also needs to move forward for you to be able to do that. Is that correct to assume?

Unknown 1
32:58 - 35:28

Uh, well, we can do it without us. If you're referring to U.S. regulatory matters. So we can proceed without that. Because in Europe, the deal size is. So, we are now discussing a revenue of 1.3 million in the first half, or whatever the number might be. But one single customer can bring double or even more revenue. So it's really hard to forecast. For example, when we closed with the Paris hospital region, I believe they have 38 hospitals. It is the largest hospital group in Europe. We were competing against a couple of key players in the market. They evaluated us and chose us. They wanted to integrate us internally. They needed to secure the budget. So they secured the budget. Everything was ready to place the order. But then, dealing with France's processes, you need to have a certain kind of procurement and purchasing process in place. The purchasing process has taken five months. It's complete now. These type of things are not easy to predict. But now, we are listed in catalogs that every other hospital in France can order from. So, we don't need to repeat the same process for them. Currently, it's two hospitals out of 38, using just a couple of our AI models, which indicates potential growth. If we expand to let's say half of the other hospitals, we are addressing a market ten times larger than Finland. To put it in perspective, it's the same size as the region of Finland. These are significant opportunities. Thus, it could potentially show exponential growth. However, it's hard to confirm that. We don't want to provide a forecast that it will definitely happen in Q4. It might happen next quarter, or the one after that. But still, we are on the right track. And you can see this from our backlog growth, which is already confirmed revenue. When we recognize revenue, it's when we deliver, and it's in production, so we could be more aggressive with estimates. However, we tend to be quite conservative in our approach. Yes, I mean for a good reason as well. Yeah.

William
35:28 - 36:27

Of course, it's according to the IFRS regulations and rules. So, one thing everyone has to understand is that we are shifting from smaller deals on the preclinical side, like selling yearly licenses and recognizing revenue on a month-to-month basis. Now we are entering into significantly larger deals with clinical sites, where recognition is entirely different from those monthly licensing revenues. And that could cause some fluctuation in the growth rates. But as you said, we need to have a higher growth rate, something close to 100% in the coming years. And I'm pretty positive that we could manage that since the figures at the moment are very low and there are a lot of opportunities that we are currently tackling.

Unknown 1
36:28 - 38:05

One thing to add is that we are transitioning from selling the research platform to research groups, focusing on ten thousand dollar deals, twenty thousand dollar deals, and some university deals. We still do that. But those deals didn't dramatically increase revenue. So, last year when we closed the window, that was roughly about 1.3 million. The deal spans three years. So, we expect that this will continue, of course, and we can grow. The deal in Spain was also quite sizable. I don't know whether we announced the numbers. I guess we did. Yeah. But okay, so it was a good deal. And, amid the fierce competition, some deals were sealed. They announced that they want the umbrella deal, and the entire purchase is valued at 6 million; it's a multi-million dollar deal at the opportunity level. The first three orders we received are already, let's say, the third biggest deal in the company's history. In the past two years, we've transitioned to the clinical side, where we are now discussing deals worth half a million, a million, 1.3 million, and even larger sums. So, that okay, so that's a transformation. So when we start recognizing those types of opportunities, then are we growing from 1.3 million to something else. Of course, we are. But now, we need to really focus on keeping the momentum, on selling, closing those big deals, and just as importantly, delivering them really well. So we want to see happy customers using the solutions as well.

Unknown 2
38:06 - 38:06

Right.

Matthew
38:06 - 38:25

So, would it be correct to interpret this as you having confidence in the sales execution and the ability to win the customers necessary to achieve those targets? But then, of course, the timing it takes for those customers to go through the purchase process, and for them to expand the usage of Aiforia, represents the risk and difficult part to estimate.

Unknown 1
38:25 - 39:14

In May, we dealt with the lengthy delivery process. We learned a lot about that. So, we fine-tune the solution to replicate easier ways that enable faster deliveries. But when you have the first one, it always takes a bit more time. Now we are learning how to do the procurement in France. Well, now we have learned that, and we can assume that the subsequent ones should happen more quickly. But of course, in the public sector, the whole tendering process has its good and bad aspects. It takes a lot of time. But when it's done, it's completed. And if you are part of that list of selected companies, then you are in a good position to move forward. In a way, it's both good and bad, but that's okay. We are learning from that as well. Yes.

Matthew
39:15 - 39:17

I believe that's all from me for now. Thank you.

Unknown 2
39:17 - 39:17

Thank you.

Operator
39:21 - 39:29

Yes, let's take some questions from the chat. Uh, the first one is, can you elaborate a bit on how your technology compares to others?

Unknown 1
39:30 - 41:38

The technology is deep learning-based AI. We are focused on image analysis. Thus, we handle large pixel files and perform pixel-level annotation. We offer two things. We have a development platform that allows you to build your own AI models. It's called Aiforia Create. Then we have ready-made AI models. These cover breast cancer, lung cancer, prostate cancer, and all kinds of regulatory approved models. So, we offer the development platform, ready-made tools, APIs, and integrations with different surrounding systems. But we deal with software, not hardware, because the process entails sample preparation, staining glass slides, and digitization with the scanners - that's mostly the hardware part. Then you have the software part, which involves sharing these images with the right pathologists and managing the workflow. This is not a simple matter either, because the files are often gigabyte-sized. So, it's really much larger than in radiology. And that is a part of the technology. Then, you have the AI. In our AI, we first delineate the areas where the problems are, and then we use software tools to calculate those areas and populate the reports. This differentiates us from most of the competition who are doing heatmap type analysis. It's essentially the first level of screening. We can actually provide support in making the diagnosis. It's a long answer, but the technology is indeed very advanced. I believe we have the best team focused on our technological side. We have a profound expertise in AI and deep learning.

Operator
41:40 - 41:52

Thank you. Let's move on to the final questions. Perhaps this is crucial, but do you have any plans to raise equity to accelerate your growth? Could you also elaborate on your M&A strategy if you have one?

William
41:53 - 42:35

Of course, we are always looking for opportunities. That's ongoing business. Regarding equity raising, currently, we have no plans, but of course, if opportunities arise that need more funding, we will consider them. Of course, we will take that opportunity as well. However, there are other sources of funding available to us. We are considering those options and deciding whether we need them or should continue with our current funding.

Operator
42:37 - 42:39

Thank you. Thanks for all the questions we received.

Unknown 1
42:40 - 42:42

Thank you very much. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…